文献速递认知障碍与痴呆帕金森病与运动障碍

帕金森病执行功能复合量表:用于临床试验中检测认知衰退的测量工具

The Parkinson's Disease Composite of Executive Functioning: A Measure for Detecting Cognitive Decline in Clinical Trials.
PubMed 文献 · Neurology · 2024-06-13

本研究利用帕金森病认知遗传学联盟的多中心数据,通过验证性因子分析构建了帕金森病执行功能复合量表(PaCEF),并评估其纵向变化、预测认知进展的能力及临床试验样本量需求。结果显示PaCEF对执行功能下降敏感,在帕金森病轻度认知障碍(PD-MCI)中基线PaCEF可显著预测痴呆时间,且较蒙特利尔认知评估(MoCA)所需样本量更小。

要点

  • PaCEF由五项神经心理测验构成,单因子模型拟合良好。
  • PD-MCI中基线PaCEF而非基线MoCA显著预测痴呆时间。
  • 以PaCEF为终点较MoCA所需样本量更小。

核心结论

  • PaCEF是检测帕金森病执行功能下降的敏感工具,尤其有益于帕金森病临床试验。

研究设计与样本

  • 采用帕金森病认知遗传学联盟的多中心横断面和纵向随访数据。
  • 纳入2010年3月至2020年2月收集的841例帕金森病患者基线数据,其中无认知障碍251例、轻度认知障碍480例、痴呆110例;平均(SD)年龄67.1(8.9)岁,女性270例(32%)。
  • 545例帕金森病患者具有纵向神经心理数据,跨度9年,平均(SD)随访4.5(2.2)年。
  • 通过验证性因子分析构建帕金森病执行功能复合量表(PaCEF)。

主要发现

  • 单因子执行功能模型拟合优秀:比较拟合指数=0.993、Tucker-Lewis指数=0.989、近似误差均方根=0.044。
  • PaCEF年均变化范围从保持认知未受损的PD-NCI参与者的每年0.246分至进展为痴呆的PD-MCI参与者的每年-0.821分。
  • 在PD-MCI中,基线PaCEF显著预测痴呆时间,而基线MoCA未显著预测。
  • 以PaCEF而非MoCA为终点时,PD-NCI试验所需样本量估计减少69%-73%,PD-MCI试验减少16%-19%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Executive functioning is one of the first domains to be impaired in Parkinson disease (PD), and the majority of patients with PD eventually develop dementia. Thus, developing a cognitive endpoint measure specifically assessing executive functioning is critical for PD clinical trials. The objective of this study was to develop a cognitive composite measure that is sensitive to decline in executive functioning for use in PD clinical trials. METHODS: We used cross-sectional and longitudinal follow-up data from PD participants enrolled in the PD Cognitive Genetics Consortium, a multicenter setting focused on PD. All PD participants with Trail Making Test, Digit Symbol, Letter-Number Sequencing, Semantic Fluency, and Phonemic Fluency neuropsychological data collected from March 2010 to February 2020 were included. Baseline executive functioning data were used to create the Parkinson's Disease Composite of Executive Functioning (PaCEF) through confirmatory factor analysis. We examined the changes in the PaCEF over time, how well baseline PaCEF predicts time to cognitive progression, and the required sample size estimates for PD clinical trials. PaCEF results were compared with the Montreal Cognitive Assessment (MoCA), individual tests forming the PaCEF, and tests of visuospatial, language, and memory functioning. RESULTS: A total of 841 participants (251 no cognitive impairment [NCI], 480 mild cognitive impairment [MCI], and 110 dementia) with baseline data were included, of which the mean (SD) age was 67.1 (8.9) years and 270 were women (32%). Five hundred forty five PD participants had longitudinal neuropsychological data spanning 9 years (mean [SD] 4.5 [2.2] years) and were included in analyses examining cognitive decline. A 1-factor model of executive functioning with excellent fit (comparative fit index = 0.993, Tucker-Lewis index = 0.989, and root mean square error of approximation = 0.044) was used to calculate the PaCEF. The average annual change in PaCEF ranged from 0.246 points per year for PD-NCI participants who remained cognitively unimpaired to -0.821 points per year for PD-MCI participants who progressed to dementia. For PD-MCI, baseline PaCEF, but not baseline MoCA, significantly predicted time to dementia. Sample size estimates were 69%-73% smaller for PD-NCI trials and 16%-19% smaller for PD-MCI trials when using the PaCEF rather than MoCA as the endpoint. DISCUSSION: The PaCEF is a sensitive measure of executive functioning decline in PD and will be especially beneficial for PD clinical trials.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Young CB, Cholerton B, Smith AM, et al. The Parkinson's Disease Composite of Executive Functioning: A Measure for Detecting Cognitive Decline in Clinical Trials. Neurology. 2024. PMID: 38870440. doi:10.1212/WNL.0000000000209609

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。